Trapidil protects ischemic hearts from reperfusion injury by stimulating PKAII activity

Cardiovascular Research

Volumn 58, Issue 3, 2003, Pages 602-610

  Sichelschmidt, Oliver J ^a   Hahnefeld, Claudia ^b   Hohlfeld, Thomas ^a   Herberg, Friedrich W ^b   Schrör, Karsten ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF KASSEL   (Germany)

Author keywords

Ischemia; Protein kinases; Reperfusion; SR (function)

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCIUM; CREATINE KINASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ISOPROTEIN; PHOSPHOLAMBAN; PROTEIN SUBUNIT; SERINE; TRAPIDIL;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; CATALYSIS; CONTROLLED STUDY; DRUG EFFECT; ESCHERICHIA COLI; HEART; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; IN VITRO STUDY; ISOLATED HEART; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; PROTEIN TARGETING; RABBIT; REGULATORY MECHANISM; REPERFUSION INJURY; SARCOPLASMIC RETICULUM; STIMULATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CARDIOTONIC AGENTS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PERFUSION; PHOSPHORYLATION; RABBITS; STIMULATION, CHEMICAL; TRAPIDIL;

EID: 0037869252     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00261-X     Document Type: Article

References (46)

1. Füller H., Hauschild F., Modersohn D., Thomas E. Pharmakologie des 5-Methyl-7-diethylamin-s-triazolo(1,5-α)pyrimidin (Trapymin, Rocornal), einer Verbindung mit koronargefäßerweiternder Wirkung. Pharmazie. 26:1971;554-562.
2. Heinroth-Hoffmann I., Krüger J., Tertov V.V., Orekhov A.N., Mest H.J. Influence of trapidil and trapidil derivatives on the content of cyclic nucleotides in human intima cells cultured from atherosclerotic plaques. Drug Dev Res. 19:1990;321-327.
3. Bethke T., Mehl H., Meyer W., et al. Effects of the triazolopyrimidine trapidil on force of contraction, beating frequency and phosphodiesterase I-IV activity in guinea-pig hearts. Arzneimittelforschung/Drug Res. 41:1991;461-468.
4. Yamaguchi K., Suzuki K., Niho T., et al. Reduction of myocardial infarct size by trapidil in anesthetized dogs. J Cardiovasc Pharmacol. 5:1983;499-505.
5. Schrör K., Zwaka P., Tannhäuser R. Cardioprotective actions of trapidil in myocardial ischemia involve inhibition of the activation of NFκB [abstract]. FASEB J. 12:(Suppl. A):1998;33.
6. Bönisch D., Weber A.A., Wittpoth M., Osinski M., Schrör K. Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A. Mol Pharmacol. 54:1998;241-248.
7. Osinski M.T., Schrör K. Trapidil mediates its antimitogenic effect by direct activation of protein kinase A II [abstract]. Naunyn Schmiedeberg's Arch Pharmacol. 359:(Suppl.3):1999;R63.
8. Cornea R.L., Jones L.R., Autry J.M., Thomas D.D. Mutation and phosphorylation change the oligomeric structure of phospholamban in lipid bilayers. Biochemistry. 36:1997;2960-2967.
9. 2+ pump and phospholamban in Spodoptera frugiperda (Sf21) cells reveals new insights on ATPase regulation. J Biol Chem. 272:1997;15872-15880.
10. Kimura Y., Kurzydlowski K., Tada M., MacLennan D.H. Phospholamban inhibitory function is activated by depolymerization. J Biol Chem. 272:1997;15061-15064.
11. Fujii J., Ueno A., Kitano K., et al. Complete complementary DNA-derived amino acid sequence of canine cardiac phospholamban. J Clin Invest. 79:1987;301-304.
12. Simmerman H.K., Collins J.H., Theibert J.L., Wegener A.D., Jones L.R. Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. J Biol Chem. 261:1986;13333-13341.
13. Colyer J. Phosphorylation states of phospholamban. Ann NY Acad Sci. 853:1998;79-91.
14. Schoutsen B., Blom J.J., Verdouw P.D., Lamers J.M. Calcium transport and phospholamban in sarcoplasmic reticulum of ischemic myocardium. J Mol Cell Cardiol. 21:1989;719-727.
15. 2+/calmodulin protein kinase phosphorylation of cardiac SR proteins in ischemia-reperfusion. Am J Physiol. 277:1999;C384-C391.
16. Jennings R.V., Sommers H.M., Kaltenbach J.P., West J.J. Electrolyte alterations in acute myocardial ischemic injury. Circ Res. 14:1964;260-269.
17. Przyklenk K., Simkhovich B.Z., Bauer B., et al. Cellular mechanisms of infarct size reduction with ischemic preconditioning. Role of calcium? Ann NY Acad Sci. 874:1999;192-210.
18. Schrör K., Zimmermann K.C., Tannhäuser R. Augmented myocardial ischaemia by nicotine - mechanisms and their possible significance. Br J Pharmacol. 125:1998;79-86.
19. Drago G.A., Colyer J. Discrimination between two sites of phosphorylation on adjacent amino acids by phosphorylation site-specific antibodies to phospholamban. J Biol Chem. 269:1994;25073-25077.
20. 2+ pump and blocking of phospholamban phosphorylation and dephosphorylation by a phospholamban monoclonal antibody. J Biol Chem. 261:1986;7018-7023.
21. Yonemoto W.M., McGlone M.L., Slice L.W., Taylor S.S. Prokaryotic expression of catalytic subunit of adenosine cyclic monophosphate-dependent protein kinase. Methods Enzymol. 200:1991;581-596.
22. Saraswat L.D., Filutowicz M., Taylor S.S. Expression of the type I regulatory subunit of cAMP-dependent protein kinase in Escherichia coli. J Biol Chem. 261:1986;11091-11096.
23. Herberg F.W., Maleszka A., Eide T., Vossebein L., Tasken K. Analysis of A-kinase anchoring protein (AKAP) interaction with protein kinase A (PKA) regulatory subunits: PKA isoform specificity in AKAP-binding. J Mol Biol. 298:2000;329-339.
24. Buechler Y.J., Herberg F.W., Taylor S.S. Regulation-defective mutants of type I cAMP-dependent protein kinase. Consequences of replacing arginine 94 and arginine 95. J Biol Chem. 268:1993;16495-16503.
25. Cook P.F., Neville M.E. Jr., Vrana K.E., Hartl F.T., Roskoski R. Jr. Adenosine cyclic 3′,5′-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit. Biochemistry. 21:1982;5794-5799.
26. Klug G.A., Knudson M.B., Cartier L.-J., Gollnick P.D. Cardiac contractility, cAMP-dependent protein kinase, and phosphorylase activation during acute pressure overload. Pflüger's Arch. 402:1984;216-221.
27. Harder S., Thürmann P.A., Hellstern A., Benjaminov A. Pharmacokinetics of trapidil, an antagonist of platelet derived growth factor, in healthy subjects and in patients with liver cirrhosis. Br J Clin Pharmacol. 42:1996;443-449.
28. Colledge M., Scott D. AKAPs: from structure to function. Trends Cell Biol. 19:1999;216-221.
29. Yang J., Drazba J.A., Ferguson D.G., Bond M. A-kinase anchoring protein 100 (AKAP100) is localized in multiple subcellular compartments in the adult rat heart. J Cell Biol. 142:1998;511-522.
30. Fink M.A., Zakhary D.R., Mackey J.A., et al. AKAP-mediated targeting of protein kinase A regulates contractility in cardiac myocytes. Circ Res. 88:2001;291-297.
31. Kranias E.G., Schwartz A., Jungmann R.A. Characterization of 3′:5′-AMP-dependent protein kinase in sarcoplasmic reticulum and cytosol of canine myocardium. Biochim Biophys Acta. 709:1982;28-37.
32. Colledge M., Dean R.A., Scott G.K., et al. Targeting of PKA to glutamate receptors through a MAGUK-AKAP complex. Neuron. 27:2000;107-119.
33. Zaccolo M., Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science. 295:2002;1711-1715.
34. Schrör K., Funke K. Prostaglandins and myocardial noradrenaline overflow after sympathetic nerve stimulation during ischemia and reperfusion. J Cardiovasc Pharmacol. 7:(Suppl. 5):1985;S50-S54.
35. Schömig A., Dart A.M., Dietz R., Mayer E., Kübler W. Release of endogenous catecholamines in the ischemic myocardium of the rat. Part A: Locally mediated release. Circ Res. 55:1984;689-701.
36. Tolnai S., Korecky B. Calcium-dependent proteolysis and its inhibition in the ischemic rat myocardium. Can J Cardiol. 2:1986;42-47.
37. McCord J.M., Roy R.S., Schaffer S.W. Free radicals and myocardial ischemia. The role of xanthine oxidase. Adv Myocardiol. 5:1985;183-189.
38. Bolli R., Cannon R.O., Speir E., Goldstein R.E., Epstein S.E. Role of cellular proteinases in acute myocardial infarction. I. Proteolysis in non-ischemic and ischemic rat myocardium and the effects of antipain, leupeptin, pepstatin and chymostatin administered in vivo. J Am Coll Cardiol. 2:1983;671-680.
39. Downing S.E. Wall tension and myocardial dysfunction after ischemia and reperfusion. Am J Physiol. 264:1993;H386-H393.
40. Osada M., Netticadan T., Tamura K., Dhalla N.S. Modification of ischemia-reperfusion-induced changes in cardiac sarcoplasmic reticulum by preconditioning. Am J Physiol. 274:1998;H2025-H2034.
41. Temsah R.M., Netticadan T., Chapman D., et al. Alterations in sarcoplasmic function and gene expression in ischemic-reperfused rat heart. Am J Physiol. 277:1999;H584-H594.
42. Jeremy R.W., Koretsune Y., Marban E., Becker L.C. Relation between glycolysis and calcium homeostasis in postischemic myocardium. Circ Res. 70:1992;1180-1190.
43. 2+ transport. Circ Res. 77:1995;88-97.
44. Mazurov A.V., Menshikov M.Y., Leytin V.L., Tkachuk V.A., Repin V.S. Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidil. FEBS Lett. 172:1984;167-171.
45. Yasue H., Ogawa H., Tanaka H., et al. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese antiplatelets myocardial infarction study (JAMIS) investigators. Am J Cardiol. 83:1999;1308-1313.
46. Raubach K.H., Vlahov V., Wolter K., Bussmann W.D. Double-blind randomized multicenter study on the efficacy of trapidil versus isosorbide dinitrate in stable angina pectoris. Clin Cardiol. 20:1997;483-488.